Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 609A in unresectable or advanced undifferentiated pleomorphic sarcoma
CTR20212425Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 609A in Malignant Fibrous Histiocytoma (MFH), sponsored by 3S Guojian Pharmaceutical. Started Mar 2022; status: active.
02
Drugs
609A
03
Conditions
Malignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on CTR20212425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212425.